Publications

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

First published: 2023 Mar

Journal: Metabolism Clinical and Experimental

Authors: S. Bianzano, A. Henrich, L. Herich, et al. (Susanna Bianzano, Andrea Henrich, Lena Herich, Brigitte Kalsch, Donald Sarubbi, Friedeborg Seitz, Thomas Forst)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

First published: 2023 Mar

Journal: Cardiovasc Diabetology

Authors: Oliver Schnell et al. (Tadej Battelino, Richard Bergenstal, Andreas L. Birkenfeld, Antonio Ceriello, Alice Cheng, Melanie Davies, Steve Edelman, Thomas Forst, Francesco Giorgino, Jennifer Green, Per‑Henrik Groop, Samy Hadjadj, Hiddo J.L.Heerspink, Marcus Hompesch, Baruch Izthak, Linong Ji, Naresh Kanumilli, Boris Mankovsky, Chantal Mathieu, Martin Miszon, Reem Mustafa, Michael Nauck, Roberto Pecoits‑Filho, Jeremy Pettus, Kari Ranta, Helena W. Rodbard,Peter Rossing, Lars Ryden, Petra‑Maria Schumm‑Draeger, Scott D. Solomon, Jan Škrha, Pinar Topsever, Tina Vilsbøll, John Wilding and Eberhard Standl);

(Bersacapavir) In Participants With Moderate Hepatic Impairment.

First published: 2023 Feb

Journal: Journal of Clinical Pharmacology

Authors: Kakuda TN, Halabi A, Klein G, Sanga M, Guinard-Azadian C, Kowalik M, Nedoschinsky K, Nangosyah J, Ediage EN, Hillewaert V, Verboven P, Goris I, Snoeys J, Palmer M, Biermer M.

Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.

First published: 2022 Dec

Journal: Clinical Pharmacology in Drug Development

Authors: Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V

Paradigmenwechsel in der Glukosekontrolle: Urin-, Blut-, interstitielle Glukosemessung.

First published: 2022 Nov

Journal: Diabetologie und Stoffwechsel

Authors: Forst T

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.

First published: 2022 Nov

Journal: Scientific Reports

Authors: Fontes MSC, Dingemanse J, Halabi A, Tomaszewska-Kiecana M, Sidharta PN

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.

First published: 2022 Oct

Journal: ERJ Open Research

Authors: Maher TM, Schlecker C, Luedtke D, Bossert S, Zoz DF, Schultz A.

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

First published: 2022 Oct

Journal: British Journal of Clinical Pharmacology

Authors: Klein S, Gashaw I, Baumann S, Chang X, Hummel T, Thuß U, Friedrich C

New strategies to improve clinical outcomes for diabetic kidney disease.

First published: 2022 Oct

Journal: BMC Medicine

Authors: Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, Halabi A, Schnell O, Streckebein M, Tuttle KR

Diabetes Mellitus and the Heart.

First published: 2022 Sep

Journal: Experimental and Clinical Endocrinology & Diabetes

Authors: Schütt K, Forst T, Birkenfeld AL, Zirlik A, Müller-Wieland D, Marx N

Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel

First published: 2022 Aug

Journal: Clinical and Translational Science

Authors: Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J.

100 Jahre Insuline Vergangenheit – Gegenwart – Zukunft / Insuline: Was können sie – worauf hoffen wir?

First published: 2022 Jul

Journal: diabetes-online

Authors: Forst T.

Pharmacokinetics, pharmacodynamics, and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.

First published: 2022 Jul

Journal: British Journal of Clinical Pharmacology

Authors: Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F.

Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials

First published: 2022 Jul

Journal: Journal of Diabetes Science and Technology

Authors: Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O.

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

First published: 2022 May

Journal: Journal of Thrombosis and Haemostasis

Authors: Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S